Bengaluru-based biopharma research is set to receive a major push after Agilent Technologies announced a strategic collaboration with Veeda Lifesciences to establish a new analytical Center of Excellence (CoE) focused on GLP-1 drugs and complex biologics development.
The partnership aims to strengthen India’s position in advanced biopharma research by combining Agilent’s analytical technology expertise with Veeda’s bioanalytical, clinical research, and regulatory capabilities. The joint platform will be based at Veeda’s Bengaluru biopharma facility and is expected to support global pharmaceutical and biotech companies working on next-generation therapies.
The new CoE will focus on developing regulatory-ready analytical workflows for complex therapies, especially GLP-1 based drugs, monoclonal antibodies, antibody-drug conjugates (ADCs), peptides, and other therapeutic proteins. These therapies require highly accurate testing, strong data integrity, and faster analytical processing to meet global regulatory standards.
The collaboration comes at a time when demand for GLP-1 drugs is rapidly increasing worldwide. These medicines, originally developed for diabetes treatment, are now also gaining massive attention for obesity management and metabolic disorders. As more pharmaceutical companies enter the segment, the need for reliable analytical and bioanalytical services has grown significantly.
According to Agilent India Country General Manager Nandakumar Kalathil, robust and regulatory-aligned analytics are becoming increasingly important as complex therapies move faster through the development pipeline. He said the collaboration with Veeda aims to support biopharma companies through workflow-driven analytical solutions that improve data quality, compliance, and confidence across different stages of drug development.
Bharat Bhardwaj, Vice President and General Manager for Asia Pacific at Agilent Technologies, said the partnership reflects the company’s commitment to helping customers with scalable and advanced solutions for drug development. He also highlighted Asia Pacific’s growing role as a hub for globally relevant biopharma research.
Veeda Lifesciences leadership described the collaboration as an important step towards building an integrated analytical ecosystem under one roof. Group CEO and Managing Director Binoy Gardi said pharmaceutical companies now require inspection-ready analytical capabilities from the very beginning of product development. He added that the partnership would help deliver faster decision-making and smoother progress from early development to manufacturing.
Dr Sanjib Banerjee, COO of Biopharma at Veeda Lifesciences, said the expanded platform would support structural analytical characterisation of complex biologics by using Veeda’s expertise in proteomics, glycoproteomics, and impurity analysis along with Agilent’s advanced mass spectrometry systems.
By combining high-end analytical instrumentation with clinical research infrastructure, the collaboration aims to offer globally aligned services for biopharma sponsors developing innovative therapies. The initiative is also expected to strengthen India’s reputation as a trusted destination for advanced pharmaceutical research and regulatory-compliant drug development services.
Subscribe Deshwale on YouTube
